Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 452

1.

Epoprostenol Does Not Affect Mortality in Neonates with Congenital Diaphragmatic Hernia.

Skarda DE, Yoder BA, Anstadt EE, Lally PA, Greene T, McFadden M, Rollins MD.

Eur J Pediatr Surg. 2014 Sep 13. [Epub ahead of print]

PMID:
25217715
[PubMed - as supplied by publisher]
2.

Oral treprostinil for the treatment of pulmonary arterial hypertension.

de Lartigue J.

Drugs Today (Barc). 2014 Aug;50(8):557-65. doi: 10.1358/dot.2014.50.8.2207312.

PMID:
25187906
[PubMed - indexed for MEDLINE]
3.

Subcutaneous treprostinil for pulmonary hypertension in chronic lung disease of infancy.

Ferdman DJ, Rosenzweig EB, Zuckerman WA, Krishnan U.

Pediatrics. 2014 Jul;134(1):e274-8. doi: 10.1542/peds.2013-2330.

PMID:
24982101
[PubMed - indexed for MEDLINE]
4.

Il buono, il brutto, il cattivo.

Saggar R, Khanna D, Forfia PR, Saggar R.

Thorax. 2014 Sep;69(9):871-2. doi: 10.1136/thoraxjnl-2014-205511. Epub 2014 May 1. No abstract available.

PMID:
24789425
[PubMed - indexed for MEDLINE]
5.

Pathological function of Ca2+-sensing receptor in pulmonary arterial hypertension.

Yamamura A.

J Smooth Muscle Res. 2014;50:8-17. Review.

PMID:
24770445
[PubMed - indexed for MEDLINE]
Free Article
6.

Epoprostenol for very low birth weight (VLBW) infants: a novel dilution protocol.

Rugolotto S, Beghini R, Cogo I, Sidoti G, Padovani EM, Pietrobelli A.

Pediatr Med Chir. 2013 Sep-Oct;35(5):223-4.

PMID:
24516943
[PubMed - indexed for MEDLINE]
7.

Incremental burden of disease in patients diagnosed with pulmonary arterial hypertension receiving monotherapy and combination vasodilator therapy.

Small M, Piercy J, Pike J, Cerulli A.

Adv Ther. 2014 Feb;31(2):168-79. doi: 10.1007/s12325-014-0094-z. Epub 2014 Jan 22.

PMID:
24449285
[PubMed - indexed for MEDLINE]
8.

Two formulations of epoprostenol sodium in the treatment of pulmonary arterial hypertension: EPITOME-1 (epoprostenol for injection in pulmonary arterial hypertension), a phase IV, open-label, randomized study.

Chin KM, Badesch DB, Robbins IM, Tapson VF, Palevsky HI, Kim NH, Kawut SM, Frost A, Benton WW, Lemarie JC, Bodin F, Rubin LJ, McLaughlin V.

Am Heart J. 2014 Feb;167(2):218-225.e1. doi: 10.1016/j.ahj.2013.08.008. Epub 2013 Oct 16.

PMID:
24439983
[PubMed - indexed for MEDLINE]
Free Article
9.

EPITOME-2: An open-label study assessing the transition to a new formulation of intravenous epoprostenol in patients with pulmonary arterial hypertension.

Sitbon O, Delcroix M, Bergot E, Boonstra AB, Granton J, Langleben D, Subías PE, Galiè N, Pfister T, Lemarié JC, Simonneau G.

Am Heart J. 2014 Feb;167(2):210-7. doi: 10.1016/j.ahj.2013.08.007. Epub 2013 Oct 3.

PMID:
24439982
[PubMed - indexed for MEDLINE]
Free Article
10.

IgG4-related disease in pulmonary arterial hypertension on long-term epoprostenol treatment.

Shirai Y, Tamura Y, Yasuoka H, Satoh T, Kuwana M.

Eur Respir J. 2014 May;43(5):1516-9. doi: 10.1183/09031936.00144013. Epub 2014 Jan 16. No abstract available.

PMID:
24435006
[PubMed - indexed for MEDLINE]
11.

Changes in right heart haemodynamics and echocardiographic function in an advanced phenotype of pulmonary hypertension and right heart dysfunction associated with pulmonary fibrosis.

Saggar R, Khanna D, Vaidya A, Derhovanessian A, Maranian P, Duffy E, Belperio JA, Weigt SS, Dua S, Shapiro SS, Goldin JG, Abtin F, Lynch JP 3rd, Ross DJ, Forfia PR, Saggar R.

Thorax. 2014 Feb;69(2):123-9. doi: 10.1136/thoraxjnl-2013-204150.

PMID:
24431095
[PubMed - indexed for MEDLINE]
12.

Effect of prostaglandin I2 analogs on macrophage inflammatory protein 1α in human monocytes via I prostanoid receptor and cyclic adenosine monophosphate.

Tsai MK, Hsieh CC, Kuo HF, Yang SN, Kuo CH, Huang MY, Tsai YM, Lee MS, Hung CH.

J Investig Med. 2014 Feb;62(2):332-9. doi: 10.231/JIM.0000000000000042.

PMID:
24402297
[PubMed - indexed for MEDLINE]
13.

Current therapies for the treatment of systemic sclerosis-related pulmonary arterial hypertension: efficacy and safety.

Murdaca G, Spanò F, Puppo F.

Expert Opin Drug Saf. 2014 Mar;13(3):295-305. doi: 10.1517/14740338.2014.872238. Epub 2014 Jan 3. Review.

PMID:
24387049
[PubMed - indexed for MEDLINE]
14.

Massive ascites in pulmonary arterial hypertension: caution with epoprostenol.

Kataoka M, Yanagisawa R, Yoshino H, Satoh T.

Ann Am Thorac Soc. 2013 Dec;10(6):726-7. doi: 10.1513/AnnalsATS.201305-115LE. No abstract available.

PMID:
24364782
[PubMed - indexed for MEDLINE]
15.

H2S inhibition of chemical hypoxia-induced proliferation of HPASMCs is mediated by the upregulation of COX-2/PGI2.

Li Y, Liu G, Cai D, Pan B, Lin Y, Li X, Li S, Zhu L, Liao X, Wang H.

Int J Mol Med. 2014 Feb;33(2):359-66. doi: 10.3892/ijmm.2013.1579. Epub 2013 Dec 9.

PMID:
24337227
[PubMed - indexed for MEDLINE]
16.

New horizons in pulmonary arterial hypertension therapies.

Galiè N, Ghofrani AH.

Eur Respir Rev. 2013 Dec;22(130):503-14. doi: 10.1183/09059180.00006613. Review.

PMID:
24293466
[PubMed - indexed for MEDLINE]
Free Article
17.

Novel medical therapies for pulmonary arterial hypertension.

O'Connell C, O'Callaghan DS, Humbert M.

Clin Chest Med. 2013 Dec;34(4):867-80. doi: 10.1016/j.ccm.2013.08.002. Review.

PMID:
24267310
[PubMed - indexed for MEDLINE]
18.

Combination therapy in pulmonary arterial hypertension.

Pugh ME, Hemnes AR, Robbins IM.

Clin Chest Med. 2013 Dec;34(4):841-55. doi: 10.1016/j.ccm.2013.08.007. Epub 2013 Oct 17. Review.

PMID:
24267308
[PubMed - indexed for MEDLINE]
19.

Parenteral and inhaled prostanoid therapy in the treatment of pulmonary arterial hypertension.

McLaughlin VV, Palevsky HI.

Clin Chest Med. 2013 Dec;34(4):825-40. doi: 10.1016/j.ccm.2013.09.003. Epub 2013 Oct 18. Review.

PMID:
24267307
[PubMed - indexed for MEDLINE]
20.

Intravenous Epoprostenol for Management of Pulmonary Arterial Hypertension during Pregnancy.

Timofeev J, Ruiz G, Fries M, Driggers RW.

AJP Rep. 2013 Oct;3(2):71-4. doi: 10.1055/s-0033-1338169. Epub 2013 Mar 18.

PMID:
24147238
[PubMed]
Free PMC Article

Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Loading ...
Write to the Help Desk